Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia

Br J Haematol. 2018 Sep;182(6):939-943. doi: 10.1111/bjh.14899. Epub 2017 Aug 18.

Authors

Nice Turazzi¹, Grazia Fazio¹, Valentina Rossi¹, Antonius Rolink², Giovanni Cazzaniga¹, Andrea Biondi¹, Chiara F Magnani¹, Ettore Biagi¹

Affiliations

¹ Centro Ricerca Tettamanti, Clinica Pediatrica, Università degli Studi di Milano-Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza, Italy.
² Department of Biomedicine, University of Basel, Basel, Switzerland.

PMID: 28832950
DOI: 10.1111/bjh.14899

No abstract available

Keywords: B-cell acute lymphoblastic leukaemia (B-ALL); TNFRSF13C (BAFF-R); chimeric antigen receptor (CAR); tumour immunotherapy.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

B-Cell Activation Factor Receptor / genetics*
Humans
Immunotherapy, Adoptive / methods*
Leukemia, B-Cell / therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Receptors, Chimeric Antigen / genetics
T-Lymphocytes / immunology
Tumor Cells, Cultured

Substances

B-Cell Activation Factor Receptor
Receptors, Chimeric Antigen
TNFRSF13C protein, human